Alibaba Debuts Cloud Computer, Delivery Robots at Cloud Computing Conference
Alibaba Cloud, the digital technologies and intelligence backbone of Alibaba Group, today unveiled a series of innovative products at its 12th annual Apsara Conference, highlighting the technology pioneer’s commitment in helping people adapt to the more digitized world and accelerate customers’ digital transformation during and after the pandemic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200916006004/en/
Alibaba Debuts First Cloud Computer (Photo: Business Wire)
A highlight is Alibaba Cloud’s first cloud computer, a palm-sized personal computer which, despite being just about 60 grams and as light as an egg, offers high-performance computing, thanks to robust back-end cloud resources. By simply connecting the cloud computer with a normal computer screen, a user can access almost unlimited computing resources anytime, anywhere, while paying on a subscription model or for the actual cloud consumption.
“We hope our cloud computer can help people access resilient computing power whenever they need to, so they can conduct complex tasks which usually require sophisticated and powerful PCs, such as video editing, animation rendering, software development, and online customer services, with a tiny personal computer at hand now,” said Jeff Zhang, President of Alibaba Cloud Intelligence. “As working from home becomes the new normal during and after the pandemic, we believe our innovation can also help users more easily enjoy the benefits of cloud computing anytime, anywhere, in a cost-effective yet secure way.”
With robust computing power, the cloud computer can reduce the rendering time of one frame high-resolution animation from 90 minutes using a traditional PC, down to only 10 minutes. In addition, the cloud computer’s system upgrades are conducted online, saving a big chunk of the normally heavy cost of PC machine upgrades and maintenance in traditional office settings. Through Alibaba Cloud's self-developed app-streaming protocol, which is designed for synergy between the cloud and the device, users can also purchase and access licensed apps and programs such Linux and Windows as well as various office applications. All user data will be stored on cloud for datacenter-grade security and protection measures. Available initially for enterprise customers, the cloud computers will be also available for purchase by individual consumers in the near future.
Alibaba Cloud also unveiled its autonomous logistics robot for last-mile deliveries. Developed by the Alibaba DAMO Academy, the global research initiative by Alibaba Group, the delivery robot can carry 50 packages at one time and cover 62 miles (or 100 kilometres) on a single charge. It is estimated the mobile robot should be able to deliver as many as 500 packages a day to one designated community or campus, meeting the rising demand for speedy last-mile delivery in China. Online shopping is booming there, with 200 million packages delivered daily and expectations that will rise to 1 billion packages per day in the coming years.
“We are expecting a rapid spike of delivery demands brought by the thriving New Retail and local services businesses in the increasingly digitalized world,” added Zhang. “To meet the strong delivery demand for our internal business growth and for the larger society, we have been investing in smart logistics, including logistics robots, for years. We are glad to launch our latest mobile delivery robot, which will support Cainiao, Alibaba’s logistics platform, to serve communities, campuses and business parks in China. “
“Moving ahead, we aim to support the delivery needs of our local services businesses and leverage our technologies for other types of service robots, such as service robots in the airport and tourism guide robots in scenic spots.”
Supported with reinforced learning technologies, the intelligent robot can schedule its route even in a crowded environment. With proprietary, high-definition positioning technology, the robot can operate even where there’s weak or no GPS signal. Leveraging a self-developed heterogeneous computing platform, 3D Point Cloud Semantic Segmentation (PCSS) technology and deep learning, the robot can also identify obstacles and predict the intended movement of passengers and vehicles a few seconds ahead of time to enhance safety.
Consumers can use either the Cainiao or Taobao mobile apps to select a preferred timeslot during the day for delivery. The robot then arrives at the designated destination, where users retrieve their packages simply by entering a passcode they receive in the app, once the robot arrives.
A slew of cloud-native products were unveiled during the Conference:
- Cloud Lakehouse: This is the next-generation big data architecture which can deliver significant data-based values and intelligence through cross-platform computing, intelligent cache, hot/cold data separation, storage improvement and performance acceleration.
- Sandboxed-Container 2.0: Alibaba’s cloud-native container service for Kubernetes supports clusters that provide sandboxed container runtimes. The new Sandboxed-Container 2.0 enables customers to run applications in lightweight sandboxed environments with faster speeds and reduced cost of runtime resources.
- PAI-DSW 2.0: The latest Cloud-native Machine-learning Interactive Development Platform by Alibaba. It aims to provide an optimal environment for developers that is easy to use, compatible with community plug-ins and supports multi-development environments like JupyterLab, WebIDE and Terminal.
- Lindorm: The cloud-native multi-model database that is used to support the Alibaba Group ecosystem, is introduced to benefit the wider Alibaba Cloud ecosystem. Lindorm is a cloud-native database, with affordable storage and flexible processing characteristics. It is designed for applications with massive processing requirements for a mixture of unstructured, semi-structured, and structured data.
The conference, named “Leap Into the Future of Digital Intelligence,” was entirely hosted online for the first time, with over 100 virtual forums on topics ranging from cloud computing, IoT to machine learning and industrial AI solutions.
For more information about the Apsara Conference, please visit the website: https://www.alibabacloud.com/apsara-conference-2020
About Alibaba Cloud
Established in 2009, Alibaba Cloud (alibabacloud.com), the digital technology and intelligence backbone of Alibaba Group, is among the world’s top three IaaS providers, according to Gartner. It is also the largest provider of public cloud services in China, according to IDC. Alibaba Cloud provides a comprehensive suite of cloud computing services to businesses worldwide, including merchants doing business on Alibaba Group marketplaces, start-ups, corporations and public services. Alibaba Cloud is the official Cloud Services Partner of the International Olympic Committee.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ESMO 2020: Cabometyx ® (cabozantinib) in Combination With Opdivo ® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial19.9.2020 18:30:00 CEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) demonstrated significant improvements across all efficacy endpoints, including overall survival (OS), in previously untreated advanced renal cell carcinoma (RCC).1 Cabometyx® in combination with Opdivo® reduced the risk of death by 40% versus sunitinib (HR: 0.60 [98.89% Confidence Interval [CI]: 0.40–0.89]; p= 0.0010; median OS not reached in either arm). In patients receiving Cabometyx® in combination with Opdivo®, median progression-free survival (PFS), the trial’s primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively (Hazard Ratio [HR]: 0.51 [95% CI 0.41–0.64], p < 0.0001). In addition, Cabometyx® in combination with Opdivo® demonstrated a superior objective response rate, wit
Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 12:55:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new
Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 12:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95
Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 09:30:00 CEST | Press release
Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu
Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 08:00:00 CEST | Press release
Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price
Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 07:00:00 CEST | Press release
Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom